<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="17822"><DrugName>Quintanrix</DrugName><DrugNamesKey><Name id="42892879">Quintanrix</Name></DrugNamesKey><DrugSynonyms><Name><Value>Infanrix-DTaP-Hep B-Hib</Value></Name><Name><Value>DTPw-HBV/Hib</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>vaccine (diphtheria/tetanus/pertussis/hepatitis B/haemophilus influenzae type b), GlaxoSmithKline</Value></Name><Name><Value>vaccine (diphtheria/tetanus/pertussis/hepatitis B/haemophilus influenzae type b), SmithKlineBeecham</Value></Name><Name><Value>Quintanrix</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>GSK-323527A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GSK-32327A</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GSK-357939A</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="19962">SmithKline Beecham plc</CompanyOriginator><CompaniesSecondary><Company id="19962">SmithKline Beecham plc</Company><Company id="28355">GlaxoSmithKline plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="17822" type="Drug"><TargetEntity id="384137" type="siDrug">DTPw-HepB-Hib</TargetEntity></SourceEntity><SourceEntity id="19962" type="Company"><TargetEntity id="5000780276" type="organizationId">Smithkline Beecham Ltd</TargetEntity></SourceEntity><SourceEntity id="28355" type="Company"><TargetEntity id="4295895781" type="organizationId">GlaxoSmithKline PLC</TargetEntity></SourceEntity><SourceEntity id="145" type="ciIndication"><TargetEntity id="1410" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"></TargetEntity><TargetEntity id="D019694" type="MeSH"></TargetEntity><TargetEntity id="-1284790527" type="omicsDisease"></TargetEntity><TargetEntity id="429" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="47" type="ciIndication"><TargetEntity id="A37" type="ICD10"></TargetEntity><TargetEntity id="033" type="ICD9"></TargetEntity><TargetEntity id="10034738" type="MEDDRA"></TargetEntity><TargetEntity id="D014917" type="MeSH"></TargetEntity><TargetEntity id="1489" type="ORPHANET"></TargetEntity><TargetEntity id="-320620987" type="omicsDisease"></TargetEntity><TargetEntity id="2337" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="72" type="ciIndication"><TargetEntity id="10043376" type="MEDDRA"></TargetEntity><TargetEntity id="D013742" type="MeSH"></TargetEntity><TargetEntity id="3299" type="ORPHANET"></TargetEntity><TargetEntity id="-687302618" type="omicsDisease"></TargetEntity><TargetEntity id="816" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="81" type="ciIndication"><TargetEntity id="A36" type="ICD10"></TargetEntity><TargetEntity id="10013023" type="MEDDRA"></TargetEntity><TargetEntity id="D004165" type="MeSH"></TargetEntity><TargetEntity id="1679" type="ORPHANET"></TargetEntity><TargetEntity id="-360770994" type="omicsDisease"></TargetEntity><TargetEntity id="3234" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="W">Withdrawn</PhaseHighest><IndicationsSecondary><Indication id="145">Haemophilus influenzae infection</Indication><Indication id="152">Hepatitis B virus infection</Indication><Indication id="47">Bordetella pertussis infection</Indication><Indication id="72">Clostridium tetani infection</Indication><Indication id="81">Corynebacterium diphtheriae infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="12378">Prophylactic vaccine</Action><Action id="12375">Toxoid vaccine</Action><Action id="12372">Protein subunit vaccine</Action><Action id="12373">Polysaccharide subunit vaccine</Action></ActionsSecondary><Technologies><Technology id="80">Peptide</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="159">Oligosaccharide</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2018-12-03T09:17:48.000Z</LastModificationDate><ChangeDateLast>2016-11-24T00:00:00.000Z</ChangeDateLast><AddedDate>1998-05-08T10:38:41.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="28355" linkType="Company"&gt;GlaxoSmithKline&lt;/ulink&gt; (GSK; formerly &lt;ulink linkID="19962" linkType="Company"&gt;SmithKline Beecham&lt;/ulink&gt;) was developing several formulations of a DTPw-HBV/Hib combination vaccine (GSK-323527A) containing the  polyribosylribitol phosphate (PRP) antigen of the Hib bacteria, presumed to include Quintanrix,  for the potential im prophylaxis of diphtheria, tetanus, pertussis, hepatitis B and Hemophilus influenzae type b (Hib)   [&lt;ulink linkID="797670" linkType="Reference"&gt;797670&lt;/ulink&gt;], [&lt;ulink linkID="939423" linkType="Reference"&gt;939423&lt;/ulink&gt;]. In May 2003, Quintanrix was filed for approval in the EU [&lt;ulink linkID="939443" linkType="Reference"&gt;939443&lt;/ulink&gt;], and in  October 2004, it was approved in the EU [&lt;ulink linkID="939442" linkType="Reference"&gt;939442&lt;/ulink&gt;]; however, in August 2008, GSK withdrew the marketing authorization for Quintanrix. There were no safety concerns regarding the vaccine, which had never been launched in the EU [&lt;ulink linkID="939423" linkType="Reference"&gt;939423&lt;/ulink&gt;]. In February 2005, a phase III trial of a vaccine for these indications began [&lt;ulink linkID="1008573" linkType="Reference"&gt;1008573&lt;/ulink&gt;]; phase III development was still ongoing in March 2009 [&lt;ulink linkID="1008602" linkType="Reference"&gt;1008602&lt;/ulink&gt;]; clinical development ended later that year [&lt;ulink linkID="1309639" linkType="Reference"&gt;1309639&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Formerly SmithKlineBeecham was developing an Infanrix combination vaccine, &lt;ulink linkID="17822" linkType="Drug"&gt;Infanrix-DTaP+Hep B+Hib&lt;/ulink&gt;, for  these indications. In April 1998, it was undergoing phase III trials outside the US [&lt;ulink linkID="284490" linkType="reference"&gt;284490&lt;/ulink&gt;]. These were ongoing at the end of 1998 [&lt;ulink linkID="328072" linkType="reference"&gt;328072&lt;/ulink&gt;], but no further development was reported since that date.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2009, a randomized, single-blind phase III trial (&lt;ulink linkID="39866" linkType="Protocol"&gt;NCT00814710&lt;/ulink&gt;; 111188) began in infants (expected n = 360) in India. The study would assess safety, reactogenicity and immunogenicity of  &lt;ulink linkID="11459" linkType="Drug"&gt;Synflorix&lt;/ulink&gt; vaccine co-administered with DTPw-HBV/Hib  vaccine to healthy infants  6 to 10 weeks old. The primary endpoint would be antibody response  to all  antigens of the Synflorix vaccine. The trial was expected to complete in October 2009 [&lt;ulink linkID="1008602" linkType="Reference"&gt;1008602&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2009, a non-randomized, open-labelled phase III trial (&lt;ulink linkID="42599" linkType="Protocol"&gt;NCT00829010&lt;/ulink&gt;; 111634) began in infants (expected n = 500) in South Africa. The primary and booster vaccination study would assess  safety, reactogenicity and immunogenicity of &lt;ulink linkID="11459" linkType="Drug"&gt;Synflorix&lt;/ulink&gt; in Human immunodeficiency virus (HIV) infected infants, HIV exposed uninfected infants or unexposed uninfected infants, when co-administered  with a rotavirus vaccine, measles vaccine and the DTPw-HBV/Hib  vaccine. The primary endpoint would be antibody response  to all  antigens of the Synflorix vaccine. The trial was expected to complete in February 2012 [&lt;ulink linkID="1008665" linkType="Reference"&gt;1008665&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2008, a  randomized, double-blind, phase III trial (&lt;ulink linkID="10061" linkType="Protocol"&gt;NCT00473668&lt;/ulink&gt;; 104977) of two tormulations of DTPw-HBV/Hib (GSK-32327A and GSK-357939A) compared to &lt;ulink linkID="12862" linkType="Drug"&gt;Tritanrix-HB&lt;/ulink&gt;, was initiated in healthy Infants (n = 300) in  India. The study was completed in January 2008 [&lt;ulink linkID="1877831" linkType="Reference"&gt;1877831&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2007, a comparative, randomized, double-blind, phase III trial (&lt;ulink linkID="10061" linkType="Protocol"&gt;NCT00473668&lt;/ulink&gt;; 104977) was initiated in healthy infants (expected n = 300) at 6, 10 and 14 weeks in India. The subjects were to receive one formulation of DTPw-HBV/Hib which would be compared to two formulations of DTPw-HBV/Hib containing the PRP antigen. The primary endpoint was an antibody response to all vaccine antigens.  The trial was completed in January 2008 [&lt;ulink linkID="797670" linkType="Reference"&gt;797670&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2006,  a randomized, double-blind, phase III trial  (&lt;ulink linkID="11244" linkType="Protocol"&gt;NCT00344318&lt;/ulink&gt;; 107007) began in infants (expected n = 806) in the Philippines and Poland. The study would assess safety, reactogenicity and immunogenicity of  &lt;ulink linkID="11459" linkType="Drug"&gt;Synflorix&lt;/ulink&gt; vaccine compared to &lt;ulink linkID="4144" linkType="Drug"&gt;Prevenar&lt;/ulink&gt;, when co-administered with DTPw-HBV/Hib  and   OPV or IPV vaccines. The primary endpoint was the occurrence of fever with rectal temperature of &amp;gt; 39Â°C. The trial completed in April 2007 [&lt;ulink linkID="1008585" linkType="Reference"&gt;1008585&lt;/ulink&gt;]. In October 2007, a  booster study (NCT00547248; 109509) began in infants (expected n = 756) who had completed the primary vaccination course in study NCT00344318. The trial completed in May 2008 [&lt;ulink linkID="1008587" linkType="Reference"&gt;1008587&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2006, a randomized, open-labelled phase III trial (NCT00332566; 106602) began in Argentina and Nicaragua. Healthy infants (expected n = 148) would receive an im booster dose of one of two different batches of  the DTPw-HBV/Hib vaccine after receiving the same vaccine for primary vaccination. The primary endpoint was an antibody response to all vaccine antigens. The trial was completed in October 2006 [&lt;ulink linkID="1008567" linkType="Reference"&gt;1008567&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2006, a randomized, double-blind, phase III trial (&lt;ulink linkID="10382" linkType="Protocol"&gt;NCT00316680&lt;/ulink&gt;; 104489) began in infants (expected n = 288) aged 2, 4 and 6 months in the Dominican Republic. The study would assess the immunogenicity, reactogenicity and safety of two different formulations of the DTPw-HBV/Hib vaccine in infants who had received a hepatitis B vaccine at birth. The primary endpoint was an antibody response to all vaccine antigens. The trial was terminated by October 2008 [&lt;ulink linkID="1008577" linkType="Reference"&gt;1008577&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2005, a randomized, active-controlled, open-labelled phase III trial (&lt;ulink linkID="10635" linkType="Protocol"&gt;NCT00169442&lt;/ulink&gt;; 104065) began in the Philippines, to assess the immunogenicity and reactogenicity of a booster dose of DTPw-HBV/Hib in infants (expected  n = 765) of 15 to 18 months previously vaccinated with the DTPw-HBV/Hib vaccine at 10 months. The primary endpoint was an antibody response to all vaccine antigens. The trial was completed by September 2006 [&lt;ulink linkID="1008573" linkType="Reference"&gt;1008573&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;By October 2006, a randomized, double-blind, placebo-controlled phase II trial (NCT00385320; 444563/006) was completed in 2 months old infants (expected n = 2640) in Brazil, Mexico and Venezuela. The study  assessed the immunogenicity, reactogenicity and safety of two different doses of a human rotavirus (HRV) vaccine co-administered with he DTPw-HBV/Hib vaccine. The primary endpoint was occurrence of rotavirus GE [&lt;ulink linkID="1008669" linkType="Reference"&gt;1008669&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2005, a randomized, active-controlled, open-labelled phase II trial (NCT00158808; 101477) began in the Philippines, to assess the immunogenicity and reactogenicity of a booster dose in infants (expected  n = 192) of 15 to 18 months previously vaccinated with two different formulations of the DTPw-HBV/Hib vaccine. The primary endpoint was anti-PRP concentration one month after the booster dose was received. The trial was completed by September 2006 [&lt;ulink linkID="1008575" linkType="Reference"&gt;1008575&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-08-29T00:00:00.000Z</StatusDate><Source id="939423" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-08-29T00:00:00.000Z</StatusDate><Source id="939423" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-08-29T00:00:00.000Z</StatusDate><Source id="939423" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-08-29T00:00:00.000Z</StatusDate><Source id="939423" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2008-08-29T00:00:00.000Z</StatusDate><Source id="939423" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="NI">Nicaragua</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="NI">Nicaragua</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="NI">Nicaragua</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="NI">Nicaragua</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="NI">Nicaragua</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28355">GlaxoSmithKline plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-12-31T00:00:00.000Z</StatusDate><Source id="1309639" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="1008567" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="1008567" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-08-31T00:00:00.000Z</StatusDate><Source id="1008585" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-08-31T00:00:00.000Z</StatusDate><Source id="1008585" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-08-31T00:00:00.000Z</StatusDate><Source id="1008585" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-08-31T00:00:00.000Z</StatusDate><Source id="1008585" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="1008567" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="1008567" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="1008567" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="NI">Nicaragua</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="1008567" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="NI">Nicaragua</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="1008567" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="NI">Nicaragua</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="1008567" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="NI">Nicaragua</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="1008567" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="NI">Nicaragua</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-06-30T00:00:00.000Z</StatusDate><Source id="1008567" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-03-31T00:00:00.000Z</StatusDate><Source id="1008587" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-03-31T00:00:00.000Z</StatusDate><Source id="1008577" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-03-31T00:00:00.000Z</StatusDate><Source id="1008577" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-03-31T00:00:00.000Z</StatusDate><Source id="1008577" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="DO">Dominican Republic</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-03-31T00:00:00.000Z</StatusDate><Source id="1008577" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-02-28T00:00:00.000Z</StatusDate><Source id="1008573" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-02-28T00:00:00.000Z</StatusDate><Source id="1008573" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-02-28T00:00:00.000Z</StatusDate><Source id="1008573" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-02-28T00:00:00.000Z</StatusDate><Source id="1008573" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="PH">Philippines</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2005-02-28T00:00:00.000Z</StatusDate><Source id="1008573" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-05-31T00:00:00.000Z</StatusDate><Source id="797670" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-05-31T00:00:00.000Z</StatusDate><Source id="797670" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-05-31T00:00:00.000Z</StatusDate><Source id="797670" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-05-31T00:00:00.000Z</StatusDate><Source id="797670" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-05-31T00:00:00.000Z</StatusDate><Source id="797670" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-02-28T00:00:00.000Z</StatusDate><Source id="1008665" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-02-28T00:00:00.000Z</StatusDate><Source id="1008665" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-02-28T00:00:00.000Z</StatusDate><Source id="1008665" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-02-28T00:00:00.000Z</StatusDate><Source id="1008665" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-02-28T00:00:00.000Z</StatusDate><Source id="1008665" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2006-08-31T00:00:00.000Z</StatusDate><Source id="1008585" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-08T00:00:00.000Z</StatusDate><Source id="284490" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-08T00:00:00.000Z</StatusDate><Source id="284490" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-08T00:00:00.000Z</StatusDate><Source id="284490" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-08T00:00:00.000Z</StatusDate><Source id="284490" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-08T00:00:00.000Z</StatusDate><Source id="284490" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-08T00:00:00.000Z</StatusDate><Source id="284490" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-08T00:00:00.000Z</StatusDate><Source id="284490" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-08T00:00:00.000Z</StatusDate><Source id="284490" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-08T00:00:00.000Z</StatusDate><Source id="284490" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19962">SmithKline Beecham plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">1998-05-08T00:00:00.000Z</StatusDate><Source id="284490" type="CONFERENCE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-10-21T00:00:00.000Z</StatusDate><Source id="939442" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-10-21T00:00:00.000Z</StatusDate><Source id="939442" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-10-21T00:00:00.000Z</StatusDate><Source id="939442" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-10-21T00:00:00.000Z</StatusDate><Source id="939442" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2004-10-21T00:00:00.000Z</StatusDate><Source id="939442" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="145">Haemophilus influenzae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-05-22T00:00:00.000Z</StatusDate><Source id="939443" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-05-22T00:00:00.000Z</StatusDate><Source id="939443" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="47">Bordetella pertussis infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-05-22T00:00:00.000Z</StatusDate><Source id="939443" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="72">Clostridium tetani infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-05-22T00:00:00.000Z</StatusDate><Source id="939443" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28355">GlaxoSmithKline plc</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="81">Corynebacterium diphtheriae infection</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2003-05-22T00:00:00.000Z</StatusDate><Source id="939443" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1570235" number="WO-09013313" title="Acellular vaccine."></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UCB SA" id="20452"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>